Is Pulmatrix, Inc. (PULM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 129.1% / 30% | 0.0% / 30% | 5.98% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 129.1% / 33% | 0.0% / 33% | 5.98% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 95.8% / 33% | 0.0% / 33% | 5.98% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 129.1% / 33% | 0.0% / 33% | 5.98% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 95.8% / 33% | 0.0% / 50% | 5.98% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -80.9% | |
| Return on Assets (ROA) | -45.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Current Ratio | 12.6 |
| Total Assets | $4M |
Price & Trading
| Last Close | $1.51 |
| 50-Day MA | $2.43 |
| 200-Day MA | $4.29 |
| Avg Volume | 30K |
| Beta | 1.7 |
|
52-Week Range
$1.32
| |
About Pulmatrix, Inc. (PULM)
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pulmatrix, Inc. (PULM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pulmatrix, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pulmatrix, Inc.'s debt ratio?
Pulmatrix, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Pulmatrix, Inc.'s key financial metrics?
Pulmatrix, Inc. has a market capitalization of $5M. Return on equity stands at -80.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.